Pandia’s menopause catalog names both progesterone and Prometrium under a capsule heading. That is a useful distinction for someone trying to identify a medicine, although it does not mean two interchangeable packages will be available for any order. The same site also offers both a prescription-transfer route and clinician access, so the service being purchased needs to be identified as carefully as the capsule.
This September 29, 2026 review examines those public records and their practical limits. It does not verify stock, a selected prescription, an insurer’s payment or the ingredients of a supplied package. Prices and plan units remain attached to the offers describing them.
In this article
The catalog gives two names that should not be blurred together
Pandia’s hormone-therapy page lists progesterone and Prometrium within its capsule navigation. The menopause service page likewise identifies those entries as available medication categories. This is direct evidence of the named offer, but not confirmation that a particular patient will be prescribed or dispensed either one.
The medicine’s brand, manufacturer and label remain important even when the active hormone is shared. Our Prometrium review examines that named product separately. It cannot authenticate Pandia’s stock or predict the pharmacy’s choice. Ask what exact product would fill the proposed prescription, rather than treating a navigation heading as the final dispensing record.
The educational list contains more than progesterone capsules
Pandia’s therapy explanation discusses progesterone, synthetic progestins and combined hormone products in different forms. These are not synonyms for a single oral capsule. A brand mentioned as an educational example does not automatically establish a selected product, and a hormone category does not identify the rest of its formulation.
The purpose guide helps separate the role of the medicine from its commercial name. The FDA menopause resource also makes treatment a benefit-risk discussion with a professional. Ask the clinician to identify each proposed active ingredient and route. This review does not turn Pandia’s descriptions of continuous or cyclical treatment into a regimen for the reader.
Prometrium’s label makes the excipient question concrete
The current DailyMed Prometrium record names peanut oil and gelatin among its inactive ingredients and states a peanut-allergy restriction. These are facts about the specified labeled product, not a conclusion that every capsule named progesterone contains the same materials. They also are not evidence of the package Pandia would supply to an individual.
The capsule-excipient guide helps frame a request for the actual manufacturer’s label. A concern about peanut, capsule material or another ingredient deserves review by the clinician and pharmacist before anyone assumes suitability. The public catalog offers a starting identity; the dispensing record is what connects that identity to the medicine actually proposed.
Existing-prescription delivery is different from buying clinician access
The Pandia service page describes transferring an existing prescription or having a clinician send one to its pharmacy, followed by verification, filling and delivery. It separately presents virtual menopause-care plans. An existing prescription route therefore should not be described as including a new clinical assessment merely because both options share the same website.
Ask which route applies and who remains responsible for treatment questions. MyMenopauseRx’s review provides a useful comparison of transfer procedures and clinician resending. Neither a successful transfer request nor free shipping would establish that a particular capsule is appropriate, covered or immediately available. These practical distinctions can prevent the wrong expectation about what a payment includes.
Read the care-plan amount with its billing period
The menopause plan record displays $69 billed monthly, a three-month option at a $59 monthly equivalent with a displayed total of 177, and an annual option at $34.99 per month with $419.88 billed annually. The three-month total has malformed currency formatting in the public text. Savings figures also differ between sections, so they are not used here to calculate a preferred offer.
Medicine costs are separate and depend on the product and coverage. The service says consultation payments are not billed to insurance, while pharmacy benefits may apply to medicines. Obtain the selected total and recurring commitment in writing. A monthly equivalent is not evidence that an annual plan can be purchased one month at a time.
Cancel-anytime wording carries a qualifying deadline
Pandia’s plan page repeats broad cancellation wording but also requires notice thirty days before the next billing period and says an early-cancellation fee may apply. These qualifications matter when assessing a longer commitment. The reviewed page does not resolve every fee or refund outcome for a selected plan.
Its refill process also describes consent and a survey about symptoms and new medicines, rather than an unconditional promise to ship indefinitely. The follow-up guide keeps a clinical renewal decision distinct from a commercial renewal. Ask how a treatment concern, changed prescription or cancellation request affects the actual order. No cancellation, payment or refill was tested in this assessment.
Broad benefit claims do not replace a capsule-specific discussion
Pandia’s service material includes wide claims about health benefits, sleep and wellbeing. Those claims do not establish that one capsule will deliver all those outcomes. FDA guidance specifically rejects using menopausal hormone therapy to prevent heart attacks, strokes or memory loss, which limits how promotional prevention language should be interpreted.
Stella’s review examines another service that combines prescribing and wider support. For practical sleep questions, use the drowsiness guide to discuss possible unwanted effects rather than assume sedation proves benefit. The useful conclusion is a named offer with unresolved individual details, not a recommendation to select a product, plan or treatment schedule.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Pandia Health: menopause hormone therapyProvider therapy and capsule catalog; names progesterone and Prometrium, no selected stock or equivalence inference; public regimens not transferred · Checked 2026-09-29
- Pandia Health: menopause care and deliveryDated provider plans and prescription-transfer offer; separate medicine cost, billing units,30-day notice and possible early fee, malformed three-month currency and inconsistent savings retained · Checked 2026-09-28
- FDA: MenopauseCurrent federal patient guidance; product-dependent benefits/risks and prevention limits, no personal eligibility or class-wide label-change inference · Checked 2026-09-29
- DailyMed: Prometrium progesterone capsulesExact Acertis product labeling updated July23,2026; oral micronized progesterone, peanut oil/gelatin and peanut-allergy restriction, not a label for every provider or generic · Checked 2026-09-29